The Effect of Regnase-1 Knockout on the Cytokine Secretion from Cord Blood Derived CAR-T Cells
As CAR-T (chimeric antigen receptor T) cells are continually modified to enhance their anti-tumor efficacy, attention must also be paid to the cytokine profiles secreted by activated CAR-T cells. These cytokines are important factors in causing the CRS (cytokine release syndrome), which is closely related to the clinical safety of CAR-T. Regnase-1 is a ribonuclease that negatively regulates the immune response. Using CRISPR/Cas9 gene editing technology, Regnase-1-deficient CAR-T cells derived from CB (cord blood) were successfully prepared. It was found that although the specific killing ability of Regnase-1–CAR-T cells was significantly stronger than that of CAR-T cells, the secretion of pro-inflammatory cytokines by Regnase-1–CAR-T cells was also significantly increased, indicating that Regnase-1–CAR-T cells were potentially risky in terms of clinical safety
CN
EN